Dear Editor, Carbapenem-resistant Enterobacteriaceae have acquired carbapenemase genes [1] , which differ substantially across countries [2] . Transferable carbapenemase IMP-type metallo-β-lactamases, particularly IMP-1 and IMP-6, are commonly identified in the clinical setting in Japan [3, 4] and exhibit different substrate specificity despite having a difference of only one amino acid (IMP-6: Ser214Gly). IMP-1 producers are more resistant to imipenem than to meropenem, whereas IMP-6 producers are more resistant to meropenem [5] . We previously found that the susceptibility rate of IMP-6-positive Escherichia coli was higher for imipenem than for meropenem [3] . Thus, IMP-6-producing isolates may be erroneously categorized as imipenem-susceptible, which could lead to treatment failure in patients.
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It is important to distinguish between the genes blaIMP-1 (encoding IMP-1) and blaIMP-6 (encoding IMP-6) because of the differences in substrate specificity; these variants can be identified by either DNA sequencing or amplification refractory mutation system (ARMS) PCR [6] . However, these methods are costly and time-consuming, and ARMS PCR requires multiple reaction tubes per sample. Therefore, we developed a simple, rapid multiplex ARMS PCR assay to discriminate between IMP-1 and IMP-6. We designed two sets of Multiplex ARMS PCR primers based on the nucleotide sequences of blaIMP-1 and blaIMP-6. Primers IMP-f and IMP-r were designed to recognize the conserved sequences of blaIMP-1 and blaIMP-6, while primers IMP-1f and IMP6r were designed to recognize specific nucleotide sequences of blaIMP-1 and blaIMP-6, respectively [7] .
PCR amplification using the primer pair IMP-1f (5´-AAGGC-AAAACTGGTTGTTCCTA-3´) and IMP-r (5´-CGACTTGTTAGAA-ATTTAGTTGC-3´) results in a 120-bp blaIMP-1 gene-specific fragment, and PCR amplification using the primer pair IMP-f (5´-CT-CGATCTATCCCCACGTATG-3´) and IMP-6r (5´-TCGTCTCCAAC-TTCACTGTGAGC-3´) generates a 350-bp blaIMP-6 gene-specific fragment (underlined sequences indicate nucleotide alternations for allele-specific primers). The 3´ termini of the primers correspond to the specific nucleotide sequence at position 640 of IMP-1 (AGT, Ser) and IMP-6 (GGT, Gly), respectively. We performed multiplex ARMS PCR amplification using the Qiagen Multiplex PCR Master Mix (Qiagen, Venlo, The Netherlands) with the following conditions: denaturation for 15 minutes at 95°C and 32 cycles of 10 seconds at 95°C, 30 seconds at 50°C, and 20 seconds at 72°C. DNA fragments were analyzed by electrophoresis. We used IMP-1-producing E. coli (NR2406) and IMP-6-producing E. coli (NR2407) from Japanese clinical isolates as positive controls. The bands, 120-or 350-bp in size, were obtained within 90 minutes or less (Fig. 1) . We performed this method on 350 carbapenemase-producing clinical isolates collected from general hospitals across Japan from 2012 to 2016 and archived in our laboratory [4, 8] .
We also determined the antibiotic susceptibility of the isolates by the agar dilution method in accordance with CLSI recommendations [9] . The multiplex ARMS PCR results and imipenem and meropenem minimum inhibitory concentration (MIC) ranges of the isolates are shown in Table 1 . The IMP-1 and IMP-6 producers yielded PCR products of the expected size. We confirmed the accuracy of this method by DNA sequencing of the PCR products (120-bp and 350-bp bands) of three representative strains. Cross-reactivity for other types of carbapenemase producers was not detected, and false-positive or false-negative results were not observed (Table 1) .
This multiplex ARMS PCR assay successfully discriminated between blaIMP-1 and blaIMP-6. Thus, this method could serve as a specific, rapid, and simple alternative for the detection of IMP-1 or IMP-6 producers and could facilitate clinical treatment, infection control, and large-scale IMP producer screening.
